Skip to main content
OpenTrials
Completed

NCT Number: NCT05090644

Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group

This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associated with schizophrenia

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Republican Scientific and Practical Center for Mental Health

Almaty, 050000, Kazakhstan

About this study

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • persons of Kazakh nationality having this ethnicity in the 3rd generation
  • age from 18 to 65 years old;
  • the dispensary in a psychiatric institution at the place of residence with a diagnosis of "Paranoid schizophrenia";
  • the duration of the disease is at least 1 year (from the moment of taking under dispensary supervision):
  • absence of severe and chronic somatic diseases;
  • absence of severe and chronic neurological diseases;
  • absence of comorbid drug addiction pathology;
  • signed informed consent to conduct this study

Exclusion criteria

  • persons of non-Kazakh nationality and Kazakh nationality, not confirmed until the 3rd generation
  • age less than 18 years old and over 65 years old;
  • those who are on dispensary registration in a psychiatric institution at the place of residence with a diagnosis not related to ICD-10 under the heading F20.0 "Paranoid schizophrenia";
  • having a disease duration of less than 1 year (from the moment of taking under dispensary supervision):
  • having severe and chronic somatic diseases;
  • having severe and chronic neurological diseases;
  • having comorbid narcological pathology;
  • not signed informed consent to conduct this study

Treatment and study plan

DNA analysis

Genetic

GWAS

Primary outcomes

  1. number of SNPs associated with schizophrenia

    Time frame: 1 year

    Using GWAS to identify candidate genes associate with schizophrenia

Sponsors and collaborators

Lead sponsor

Asfendiyarov Kazakh National Medical University

Other

Registry information

Official study title

Preventive and Personalized Medicine (2021-2023)

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Oct 25, 2021
Registry last updated
Mar 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.